GlassScriptPhysician profile
Faizan Hafeez
NPI 1386630432
$336,575.77
in general payments reported to CMS, 2019-2025
50 companies · $67K in 2025
The $67K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $42K · 2021: $72K · 2022: $55K · 2023: $20K · 2024: $27K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Honoraria: $25K · Food and Beverage: $12K · Travel and Lodging: $3,829 · Consulting Fee: $1,525 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,281.25 |
| Honoraria | $24,652.50 |
| Food and Beverage | $11,698.01 |
| Travel and Lodging | $3,829.40 |
| Consulting Fee | $1,525.00 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124,283.59 | 2021-2025 | |
| Amgen INC. | $46,979.30 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $46,883.82 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Allergan, INC. | $39,070.17 | 2019-2022 | |
| Axsome Therapeutics, INC. | $28,238.48 | 2023-2025 | Symbravo, Sunosi |
| Biohaven Pharmaceuticals, INC. | $19,326.41 | 2020-2021 | |
| Pfizer INC. | $12,559.01 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $10,510.31 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Supernus Pharmaceuticals, INC. | $958.59 | 2019-2022 | |
| Emd Serono, INC. | $924.97 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $862.23 | 2021-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $851.14 | 2020-2025 | Xcopri |
| Biohaven Pharmaceutical Holding Company LTD. | $808.98 | 2022 | |
| Lundbeck LLC | $465.60 | 2020-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $455.71 | 2019-2024 | Rytary |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faizan Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.